The Trump Administration has recently issued an executive order imposing a 100% tariff on patented pharmaceutical products imported into the United States unless manufacturers agree to government drug pricing arrangements or commit to producing the drugs domestically.
Amanda Tan of DBS Group Research has maintained her "buy" call and US$2 target price on UltraGreen.ai as she believes that recent price reactions to US tariffs on pharmaceuticals is uncalled for and that the current weakness is an opportunity for investors to accumulate.
From the recent peak of US$1.86 on Feb 23, UltraGreen.ai shares have dipped by more than a fifth.
